Abstracts tagged "Sjogren’s syndrome and abatacept"

Abstract Number: 1907 • ACR/ARP Annual Meeting 2019
Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Jacques-Eric Gottenberg¹, Sumanta Mukherjee ², Marleen Nys ³, Robert Wong ⁴, Hendrika Bootsma ⁵ and Neelanjana Ray ⁴, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁴Bristol-Myers Squibb, Princeton, ⁵University of Groningen, Groningen, Netherlands
Background/Purpose: Chemokine (C-X-C motif) ligand 13 (CXCL13), produced by follicular helper T (Tfh) cells, plays a pivotal role in B-cell homing and activation in germinal…
Abstract Number: 1124 • ACR/ARHP Annual Meeting 2015
Bruton’s Tyrosine Kinase Levels Are Increased in B Cells from Patients with Primary Sjögren’s Syndrome
Odilia B.J. Corneth¹, Gwenny Verstappen², Marjolein de Bruijn¹, Erlin A. Haacke³, Arjan Vissink⁴, Hendrika Bootsma⁵, Frans G.M. Kroese² and Rudi W. Hendriks¹, ¹Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Upon B cell receptor stimulation, B cells increase protein expression levels of the key downstream signaling molecule Bruton’s tyrosine kinase (BTK). BTK-transgenic mice that…
Abstract Number: 2553 • ACR/ARHP Annual Meeting 2012
Histological, Serological and Clinical Changes in Response to Abatacept Treatment of Sjögren’s Syndrome
Sabine Adler¹, Meike Koerner², Frauke Foerger³, Marco-Domenico Caversaccio⁴ and Peter M. Villiger⁵, ¹Rheumatology, University Hospital Bern, Bern, Switzerland, ²Pathology, University Hospital Bern, Bern, Switzerland, ³Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁴Ear Nose and Throat, University Hospital Bern, Inselspital, Bern, Switzerland, ⁵Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: To prospectively evaluate histopathologic, blood and clinical responses to abatacept treatment in patients with primary Sjögren’s syndrome (pSS). Methods: Blood, saliva and minor salivary…